

Literatura ACTA MEDICINAE 11–13/2023 Onkologie | Hematoonkologie | Hematologie

- 3 **Adjuvantní léčba nádorů ledvin**
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň, Plzeň-Lochotín
- 3 **Léčba poškození ledvin monoklonálním imunoglobulinem a volnými lehkými řetězci**
prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika, LF MU a FN Brno
MUDr. Soňa Štěpánková, Ph.D. Centrum kardiovaskulární a transplantační chirurgie, Brno
MUDr. Ing. David Zeman, Ph.D. Ústav laboratorní medicíny – oddělení klinické biochemie, LF MU a FN Brno
prof. MUDr. Luděk Pour, Ph.D. Interní hematologická a onkologická klinika, LF MU a FN Brno
MUDr. Aleš Čermák, Ph.D. Urologická klinika, LF MU a FN Brno MUDr. Petr Benda, MHA Chirurgická klinika, LF MU a FN Brno
- 4 **Místo chemoterapie v léčbě metastatického hormonálně závislého karcinomu prsu**
prof. MUDr. Petra Tesařová, CSc. Ústav radiční onkologie FNB a 1. LF UK a Onkologická klinika VFN a 1. LF UK, Praha
- 5 **Léčba triple negativního karcinomu prsu sacituzumab govitecanem – kazuistika**
MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno
- 5 **HER2 low nádory prsu a přístup k nim**
MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
- 6 **Nové postavení inhibitorů CDK4/6 v léčbě časného karcinomu prsu**
MUDr. Vlastimila Čmejlová Onkologická klinika 2. LF UK a FN v Motole, Praha
- 6 **Léčba nádorů jícnu a gastroezofageální jankce**
MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 6 **Moderní léčba nádorů žlučníku a žlučových cest se zaměřením na imunoterapii**
MUDr. Michal Eid Interní hematologická a onkologická klinika FN Brno a LF MU, Brno
- 6 **Buprenorfin v onkologické paliativní péči**
MUDr. Ondřej Sláma, Ph.D. Centrum paliativní péče, Masarykův onkologický ústav, Brno
- 7 **Karcinom plic na ASCO 2023**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 7 **Současné postavení monoterapie anti-PD-1 protilátkami v léčbě pokročilého melanomu**
MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika 1. LF UK a Všeobecná fakultní nemocnice, Praha
- 7 **Přehled nejvýznamnějších změn v 5. vydání WHO klasifikace lymfoidních nádorů**
MUDr. Vít Campr Ústav patologie a molekulární medicíny 2. LF UK a FN v Motole, Praha
- 7 **Imunoterapie kožních lymfomů**
MUDr. Kamila Polgárová, Ph.D. Interní klinika – klinika hematologie, 1. LF UK a VFN, Praha
- 8 **Imunoterapie u klasického Hodgkinova lymfomu**
MUDr. Juraj Ďuraš | MUDr. Michal Kaščák | prof. MUDr. Roman Hájek, CSc. Klinika hematoonkologie, FN Ostrava; Klinika hematoonkologie, Lékařská fakulta, Ostravská univerzita
- 9 **Cílená terapie u difuzního velkobuněčného B lymfomu**
MUDr. Prokop Vodička | prof. MUDr. Marek Trněný, CSc. I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha
- 9 **Cílená terapie u lymfomu z buněk pláště**
MUDr. Aleš Obr, Ph.D. Hemato-onkologická klinika LF UP a FN Olomouc
- 10 **Novinky v klasifikaci myeloidních neoplazií: klasifikace WHO a ICC**
RNDr. Monika Belíčková, Ph.D. Ústav hematologie a krevní transfuze, Praha
- 10 **Cílená terapie chronické myeloidní leukemie**
MUDr. Petra Čičátková | doc. MUDr. Daniela Žáčková, Ph.D. Interní hematologická a onkologická klinika FN Brno a LF MU, Brno
- 10 **Dlouhodobé výsledky podání venetoklaxu s anti-CD20 protilátkou v časově omezené délce léčby – studie CLL14 a MURANO**
MUDr. Heidi Móciková, Ph.D. Hematologická klinika FN KV a 3. LF UK, Praha

- 11 [Vyxeos Liposomal a jeho role v terapii akutní myeloidní leukemie – první zkušenosti s jeho použitím v ÚHKT Praha – kazuistiky](#)
MUDr. Jan Válka, Ph.D. | MUDr. Petr Soukup, MHA Ústav hematologie a krevní transfuze, Praha
- 11 [Léčba belantamabem v pátém relapsu mnohočetného myelomu – kazuistika](#)
MUDr. Jan Straub I. interní klinika – klinika hematologie, VFN a 1. LF UK, Praha

Adjuvantní léčba nádorů ledvin

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň, Plzeň-Lochotín

- 1 Choueiri, T. K., et al.: Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. *N Engl J Med*, 2021, 385, s. 683–694.
- 2 Dostupné z: clinicaltrials.gov/ct2/show/NCT03142334, vyhledáno 25. 5. 2021.
- 3 Choueiri, T. K., et al.: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. *J Clin Oncol*, 2021, 39, suppl. 18, DOI: 10.1200/JCO.2021.39.15_suppl.LBA5.
- 4 Choueiri, T. K. – Tomczak, P. – Park, S. H., et al.: Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Dostupné z: <https://meetings.asco.org/abstracts-presentations/205370>, vyhledáno 16. 8. 2023.

Léčba poškození ledvin monoklonálním imunoglobulinem a volnými lehkými řetězci

prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika, LF MU a FN Brno

MUDr. Soňa Štěpánková, Ph.D. Centrum kardiovaskulární a transplantáční chirurgie, Brno

MUDr. Ing. David Zeman, Ph.D. Ústav laboratorní medicíny – oddělení klinické biochemie, LF MU a FN Brno

prof. MUDr. Luděk Pour, Ph.D. Interní hematologická a onkologická klinika, LF MU a FN Brno

MUDr. Aleš Čermák, Ph.D. Urologická klinika, LF MU a FN Brno MUDr. Petr Benda, MHA Chirurgická klinika, LF MU a FN Brno

- 1 Študla, V. – Minařík, J. – Píka, T.: Nemoc z ukládání lehkých řetězců imunoglobulinu (light chain deposition disease). *Vnitř Lék*, 2012, 58, s. 38–43.
- 2 Špička, I. – Merta, M. – Cieslar, P., et al.: Postižení ledvin u monoklonálních gamapatií. Klinická studie. *Čas Lék Čes*, 1995, 134, s. 478–481.
- 3 Safránek, R. – Radocha, J. – Maisnar, V., et al.: Výsledky léčby nemocných s mnohočetným myelomem a současným renálním postižením. *Klin Biochem Metab*, 2016, 24, s. 133–135.
- 4 Špička, I. – Merta, M. – Cieslar, P., et al.: Postižení ledvin u monoklonálních gamapatií. *Čas Lék Čes*, 1996, 135, s. 374–377.
- 5 Ryšavá, R.: Renální selhání u mnohočetného myelomu a jeho léčba. *Vnitř Lék*, 2020, 66, s. 425–431.
- 6 Štěpánková, S. – Šurel, S. – Řehořová, J.: Chronická renální insuficience společným pohledem praktického lékaře a nefrologa. *Med Pro Praxi*, 2008, 5, s. 98–100.
- 7 Zima, T. – Racek, J. – Ryšavá, R., et al.: Doporučení k diagnostice chronického onemocnění ledvin (odhad glomerulární filtrace a vyšetření proteinurie). *Klin Biochem Metab*, 2021, 29, s. 94–103.
- 8 Dimopoulos, M. A. – Sonneveld, P. – Leung, N., et al.: International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. *J Clin Oncol*, 2016, 34, s. 1544–1557.
- 9 Leung, N. – Rajkumar, S. V.: Multiple myeloma with acute light chain cast nephropathy. *Blood Cancer J*, 2023, 13, s. 46.
- 10 Mené, P. – Stoppacciaro, A. – Lai, S., et al.: Light chain cast nephropathy in multiple myeloma: prevalence, impact and management challenges. *Int J Nephrol Renovasc Dis*, 2022, 15, s. 173–183.
- 11 Leung, N. – Bridoux, F. – Hutchison, C. A., et al.: International Kidney and Monoclonal Gammopathy Research Group Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. *Blood*, 2012, 120, s. 4292–4295.
- 12 Leung, N. – Bridoux, F. – Batuman, V., et al.: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nat Rev Nephrol*, 2019, 15, s. 45–59, dostupné z: <https://www.nature.com/articles/s41581-018-0077-4>, vyhledáno 18. 9. 2023.
- 13 Kurfürstová, I. – Šálek, T. – Kadlčíková, E.: Renální insuficience při onemocnění myelomem z lehkých řetězců. *Interní Med*, 2014, 16, s. 164–166.
- 14 Adam, Z. – Starý, K. – Kubinyi, J., et al.: Hyperkalcemie, příznaky, diferenciální diagnostika a léčba aneb důležitost vyšetřování kalcia. *Vnitř Lék*, 2016, 62, s. 370–383.
- 15 Štěpánková, S. – Šuel, S. – Řehořová, J., et al.: Starší nemocný a potenciálně nefrotoxická medikace. *Vnitř Lék*, 2008, 54, s. 916.
- 16 Štěpánková, S. – Šurel, S. – Řehořová, J.: Kontrastem indukovaná nefropatie a nefrogenní systémová fibróza. *Vnitř Lék*, 2007, 53, suppl. P42.
- 17 Adam, Z. – Štěpánková, S. – Sirotková, L., et al.: Selhání ledvin u pacientky s chronickou B-lymfocytární leukémií (B-CLL) vzniklé na podkladě tvorby odliškových válců v tubulech ledvin z monoklonálních volných lehkých řetězců (cast nephropathy). Přínos stanovení volných lehkých řetězců imunoglobulinů pro časnou diagnostiku této komplikace. *Vnitř Lék*, 2011, 57, s. 214–221.
- 18 Stacul, F. – Bertolotto, M. – Thomsen, H. S., et al.: ESUR Contrast Media Safety Committee. Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. *Eur Radiol*, 2018, 28, s. 683–691.
- 19 Kusirín, P. – Chattipakorn, S. C. – Chattipakorn, N.: Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. *J Transl Med*, 2020, 18, s. 400.
- 20 Mussap, M. – Merlini, G.: Pathogenesis of renal failure in multiple myeloma: any role of contrast media? *Biomed Res Int*, 2014, 2014, 167125.
- 21 Bridoux, F. – Leung, N. – Belmouaz, M., et al.: International Kidney and Monoclonal Gammopathy Research Group. Management of acute kidney injury in symptomatic multiple myeloma. *Kidney Int*, 2021, 99, s. 570–580.
- 22 Terpos, E. – Raje, N. – Croucher, P., et al.: Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. *Blood Adv*, 2021, 5, s. 725–736.
- 23 Gopaul, A. – Kanagalingam, T. – Thain, J., et al.: Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. *Arch Osteoporos*, 2021, 16, s. 116.
- 24 Thongprayoon, C. – Acharya, P. – Acharya, C., et al.: Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. *Osteoporos Int*, 2018, 29, s. 1737–1745.
- 25 Hutchison, C. A. – Cockwell, P. – Reid, S., et al.: Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. *J Am Soc Nephrol*, 2007, 18, s. 886–895.
- 26 Walther, C. – Podoll, A. S. – Finkel, K. W.: Treatment of acute kidney injury with cast nephropathy. *Clin Nephrol*, 2014, 82, s. 1–6.
- 27 Hutchison, C. A. – Harding, S. – Mead, G., et al.: Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. *Artif Organs*, 2008, 32, s. 910–917.
- 28 Hutchison, C. A. – Bradwell, A. R. – Cook, M., et al.: Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. *Clin J Am Soc Nephrol*, 2009, 4, s. 745–754.
- 29 Lachmanová, J. – Tesař, V. – Ryšavá, R., et al.: Teralite a mnohočetný myelom. *Vnitř Lék*, 2016, 62, suppl. 6, s. 9–13.
- 30 Orság, J. – Minařík, J. – Kosatíková, Z., et al.: „High cut-off“ hemodialyza – nová možnost v terapii ledvinního selhání u mnohočetného myelomu. *Med Prax*, 2014, 16, s. 192–195.
- 31 Bridoux, F. – Carron, P. L. – Pegourie, B., et al.: Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy. *JAMA*, 2017, 318, s. 2099–2110.
- 32 Bridoux, F. – Carron, P. L. – Pegourie, B.: HCO hemodialyza v léčbě myelomové ledviny: výsledky studie MYRE. *Postgraduální nefrologie*, 2018, 16, s. 14–15.
- 33 Hutchison, C. A. – Cockwell, P. – Moroz, V., et al.: High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a Phase 2 randomised controlled trial. *Lancet Haematol*, 2019, 6, s. e217–e228.
- 34 Steiner, N. – Abdel Hamid, A. – Kronbichler, A., et al.: Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury. *J Nephrol*, 2021, 34, s. 1263–1270.
- 35 Fabbri, P. – Finkel, K. – Gallieni, M., et al.: Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. *J Nephrol*, 2016, 29, s. 735–746.
- 36 Lachmanová, J. – Hrušková, Z. – Ryšavá, R., et al.: Teralite a mnohočetný myelom – známe už odpověď na efektivitu léčby nefrologa s hematologem? *Transfuzie a hematologie dnes*, 2020, 26, s. 131–138.
- 37 Wolley, M. – Jardine, M. – Hutchison, C. A.: Exploring the clinical relevance of providing increased removal of large middle molecules. *Clin J Am Soc Nephrol*, 2018, 13, s. 805–814.
- 38 Krishnasamy, R. – Hawley, C. M. – Jardine, M. J., et al.: Design and methods of the REMOVAL-HD study: a trial evaluating mid cut-off value membrane clearance of albumin and light chains in haemodialysis patients. *BMC Nephrol*, 2018, 19, s. 89.
- 39 Kim, T. H. – Kim, S. H. – Kim, T. Y., et al.: Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study. *BMC Nephrol*, 2019, 21, s. 2.
- 40 Kandi, M. – Brignardello-Petersen, R. – Couban, R., et al.: Effects of medium cut-off versus high-flux hemodialysis membranes on biomarkers: a systematic review and meta-analysis. *Can J Kidney Health Dis*, 2022, 9, 20543581211067090.
- 41 Dimopoulos, M. A. – Terpos, E. – Chanan-Khan, A., et al.: Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. *J Clin Oncol*, 2010, 28, s. 4976–4984.
- 42 Bozic, B. – Rutner, J. – Zheng, C. H., et al.: Advances in the treatment of relapsed refractory multiple myeloma in patients with renal insufficiency: novel agents, immunotherapy and beyond. *Cancers*, 2021, 13, s. 5036.
- 43 Eriksson, T. – Höglund, P. – Turesson, I., et al.: Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. *J Pharm Pharmacol*, 2003, 55, s. 1701–1706.
- 44 Tosi, P. – Zamagni, E. – Cellini, C., et al.: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. *Eur J Haematol*, 2004, 73, s. 98–103.
- 45 Mikhael, J. – Manola, J. – Dueck, A. C., et al.: Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: Pre1003, a PRiCOG study. *Blood Cancer J*, 2018, 8, s. 86.
- 46 Oehrlin, K. – Langer, C. – Sturm, I., et al.: Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: Results of 4 German centers. *Clin Lymphoma Myeloma Leuk*, 2012, 12, s. 191–196.
- 47 Specter, R. – Sanchorawala, V. – Seldin, D. C., et al.: Kidney dysfunction during lenalidomide treatment for AL amyloidosis. *Nephrol Dial Transplant*, 2011, 26, s. 881–886.
- 48 Wanchoo, R. – Abudayyeh, A. – Doshi, M., et al.: Renal toxicities of novel agents used for treatment of multiple myeloma. *Clin J Am Soc Nephrol*, 2017, 12, s. 176–189.
- 49 Krein, N. – Khateeb, A. – Gino-Moor, S., et al.: Acute renal failure associated with lenalidomide treatment in multiple myeloma: a rare occurrence? *Anticancer Res*, 2016, 36, s. 2889–2892.
- 50 Gaballa, M. R. – Laubach, J. P. – Schlossman, R. L., et al.: Management of myeloma-associated renal dysfunction in the era of novel therapies. *Expert Rev Hematol*, 2012, 5, s. 51–66.
- 51 Dimopoulos, M. – Weisel, K. – Van De Donk, N. W., et al.: Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: results from a phase II trial. *J Clin Oncol*, 2018, 36, s. 2035–2043.
- 52 Siegel, D. S. – Schiller, G. J. – Song, K. W., et al.: Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. *Br J Haematol*, 2019, 188, s. 501–510.
- 53 Miguel, J. S. – Weisel, K. – Moreau, P., et al.: Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. *Lancet Oncol*, 2013, 14, s. 1055–1066.
- 54 Weisel, K. C. – Dimopoulos, M. A. – Moreau, P.: Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. *Haematologica*, 2016, 101, s. 872–878.
- 55 Van de Donk, N. – Propat, R. – Larsen, J., et al.: First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed/refractory multiple myeloma (RRMM). *Blood*, 2020, 136, suppl. 51, s. 16–17.
- 56 Chanan-Khan, A. A. – Miguel, J. S. – Jagannath, S., et al.: Novel

- therapeutic agents for the management of patients with multiple myeloma and renal impairment. *Clin. Cancer Res*, 2012, 18, s. 2145–2163.
- 57 **Ludwig, H. – Drach, J. – Graf, H., et al.**: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. *Haematologica*, 2007, 92, s. 1411–1414.
 - 58 **Badros, A. Z. – Vij, R. – Martin, T., et al.**: Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety. *Leukemia*, 2013, 27, s. 1707–1714.
 - 59 **Dimopoulos, M. – Siegel, D. – White, D. J., et al.**: Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR. *Blood*, 2019, 133, s. 147–155.
 - 60 **Zou, Y. – Ma, X. – Yu, H., et al.**: Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: A meta-analysis of 37 trials. *Oncotarget*, 2017, 8, s. 39805–39817.
 - 61 **Sonneveld, P. – Zweegman, S. – Cavo, M., et al.**: Carfilzomib, pomalidomide and dexamethasone (KpD) in patients with multiple myeloma refractory to bortezomib and lenalidomide. the EMN011 Trial. *Blood*, 2018, 132, suppl. S1, s. 801.
 - 62 **Ball, S. – Behera, T. R. – Anwer, F., et al.**: Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. *Ann Hematol*, 2020, 99, s. 1265–1271.
 - 63 **Dimopoulos, M. A. – Moreau, P. – Palumbo, A., et al.**: Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomized, phase 3, open-label, multicenter study. *Lancet Oncol*, 2016, 17, s. 27–38.
 - 64 **Shah, J. J.**: Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. *Oncology*, 2013, 27, suppl. 3, s. 19–23.
 - 65 **Georgoulis, V. – Haidich, A. B. – Bougioukas, K. I., et al.**: Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews. *Crit Rev Oncol Hematol*, 2022, 180, s. 103842.
 - 66 **Tzoganis, K. – Florez, B. – Markey, G., et al.**: European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. *ESMO Open*, 2019, 4, s. e000570.
 - 67 **Gupta, N. – Hanley, M. J. – Harvey, R. D., et al.**: A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. *Br J Haematol*, 2016, 174, s. 748–759.
 - 68 **Montefusco, V. – Mussetti, A. – Salas, M. O., et al.**: Old and new generation proteasome inhibitors in multiple myeloma. *Panminerva Med*, 2020, 62, s. 193–206.
 - 69 **Terpos, E. – Ramasamy, K. – Maouche, N., et al.**: Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. *Ann Hematol*, 2020, 99, s. 1049–1061.
 - 70 **Kuzume, A. – Tabata, R. – Terao, T., et al.**: Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure. *Br J Haematol*, 2021, 193, s. e33–e36.
 - 71 **Kastritis, E. – Terpos, E. – Symeonidis, A., et al.**: Daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results on efficacy and safety of the phase 2 DARE study. *Blood*, 2020, 136, suppl. S1, s. 48–49.
 - 72 **Zand, L. – Rajkumar, S. V. – Leung, N., et al.**: Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits. *J Am Soc Nephrol*, 2021, 32, s. 1163–1173.
 - 73 **Dimopoulos, M. A. – Leleu, X. – Moreau, P., et al.**: Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. *Leukemia*, 2021, 35, s. 562–572.
 - 74 **Shen, F. – Shen, W.**: Isatuximab in the treatment of multiple myeloma: a review and comparison with daratumumab. *Technol Cancer Res Treat*, 2022, 21, 15330338221106563.
 - 75 **Hsi, E. D. – Steinle, R. – Balasa, B., et al.**: CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. *Clin Cancer Res*, 2008, 14, s. 2775–2784.
 - 76 **Berdeja, J. – Jagannath, S. – Zonder, J., et al.**: Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase 1b study. *Clin Lymphoma Myeloma Leuk*, 2016, 16, s. 129–138.
 - 77 **Ide, T. – Osawa, M. – Sanghavi, K., et al.**: Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. *Cancer Chemother Pharmacol*, 2022, 89, s. 129–140.
 - 78 **Tai, Y. T. – Mayes, P. A. – Acharya, C., et al.**: Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood*, 2014, 123, s. 3128–3138.
 - 79 **Lonial, S. – Lee, H. C. – Badros, A., et al.**: Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*, 2020, 21, s. 207–221.
 - 80 **Salem, A. H. – Agarwal, S. K. – Dunbar, M., et al.**: Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. *J Clin Pharmacol*, 2017, 57, s. 484–492.
 - 81 **Chauhan, D. – Velankar, M. – Brahmandam, M., et al.**: A novel BCL-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. *Oncogene*, 2007, 26, s. 2374–2380.
 - 82 **Kumar, S. K. – Harrison, S. J. – Cavo, M., et al.**: Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol*, 2020, 21, s. 1630–1642.
 - 83 **Gupta, S. – Portales-Castillo, I. – Daher, A., et al.**: Conventional chemotherapy nephrotoxicity. *Adv Chronic Kidney Dis*, 2021, 28, s. 402–414.e1.
 - 84 **Shaw, P. J. – Nath, C. E. – Lazarus, H. M.**: Not too little, not too much—just right (Better ways to give high dose melphalan). *Bone Marrow Transplant*, 2014, 49, s. 1457–1465.
 - 85 **Lee, S. Y. – Meehan, R. S. – Sedlin, D. C., et al.**: Effect of severe hypoalbuminemia on toxicity of high dose melphalan and autologous stem cell transplantation in patients with AL-Amyloidosis. *Bone Marrow Transplant*, 2016, 51, s. 1318–1322.
 - 86 **Sidiqi, M. H. – Nadiminti, K. – Al Saleh, A. S., et al.**: Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. *Bone Marrow Transplant*, 2019, 54, s. 1775–1779.
 - 87 **San Miguel, J. F. – Lahuerta, J. J. – Garcia-Sanz, R., et al.**: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? *Hematol J*, 2000, 1, s. 28–36.
 - 88 **Krejčí, J. – Doubek, M. – Hájek, R., et al.**: Autologní transplantace periferních hemopoetických buněk u nemocných s mnohočetným myelomem a renální insuficiencí. *Vnitř Lék*, 1997, 43, s. 756–758.
 - 89 **Badros, A. – Barlogie, B. – Siegel, E., et al.**: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. *Br J Haematol*, 2001, 114, s. 822–829.
 - 90 **Řehořová, J. – Smržová, J. – Šurel, S., et al.**: Dialyzovaný pacient a deprese. *Vnitř Lék*, 2007, 53, suppl. s. P40.
 - 91 **Štěpánková, S. – Kuman, M., et al.**: Zařazování na čekateckou listinu transplantace ledviny. *TiGis*, 2012, 18, suppl. 1, s. 35–37.
 - 92 **Štěpánková, S. – Kuman, M. – Mezlik, V., et al.**: Kombinovaná transplantace srdce a ledviny u pacienta s AA amyloidózou. *TiGis*, 2016, 22, suppl. 1, s. 50–52.
 - 93 **Štěpánková, S. – Malásková, L.**: Transplantace ledviny u pacienta pokročilého věku. *TiGis*, 2021, 27, s. 27–31.
 - 94 **Spitzer, T. R. – Sykes, M. – Tollock-Rubin, N., et al.**: Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. *Transplantation*, 2011, 91, s. 672–676.
 - 95 **Huskey, J. L. – Heilman, R. L. – Khamash, H., et al.**: Kidney transplant in the era of modern therapy for multiple myeloma. *Transplantation*, 2018, 102, s. 1994–2001.
 - 96 **Chitty, D. W. – Hartley-Brown, M. A. – Abate, M., et al.**: Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades. *Nephrol Dial Transplant*, 2022, 37, s. 1616–1626.
 - 97 **Lim, W. H. – Au, E. – Krishnan, A., et al.**: Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink? *Transpl Int*, 2019, 32, s. 1223–1240.
 - 98 **Lum, E. L. – Bunnapradist, S.**: Current opinions in nephrology and hypertension: kidney transplantation in patients with plasma cell dyscrasias. *Curr Opin Nephrol Hypertens*, 2019, 28, s. 573–580.
 - 99 **Havasi, A. – Heybeli, C. – Leung, N., et al.**: Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group. *Blood Cancer J*, 2022, 12, s. 119.
 - 100 **Ng, J. H. – Izard, S. – Murakami, N., et al.**: Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA. *Nephrol Dial Transplant*, 2022, 37, s. 2569–2580.
 - 101 **Adam, Z. – Ozabalová, E. – Némec, P., et al.**: Transplantace srdce a následující léčba AL-amyloidózy u 5 pacientů. *Vnitř Lék*, 2018, 64, s. 441–449.
 - 102 **Teplan V.**: Multimorbidita při nefrotickém syndromu. *Vnitř Lék*, 2023, 69, s. 156–165.
 - 103 **Courant, M. – Orazio, S. – Monnerau, A., et al.**: Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. *Nephrol Dial Transplant*, 2021, 36, s. 482–490.
 - 104 **Almaani, S. – Parikh, S. V. – Satoskar, A. A., et al.**: Daratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits. *Kidney Int Rep*, 2021, 6, s. 2203–2206.
 - 105 **Coltoff, A. – Bomback, A. – Shirazian, S., et al.**: Treatment of monoclonal gammopathy-associated C3 glomerulopathy with daratumumab-based therapy. *Clin Lymphoma Myeloma Leuk*, 2021, 21, s. e674–e677.
 - 106 **Kastritis, E. – Rousakis, P. – Kostopoulos, I. V., et al.**: Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. *Amyloid*, 2021, 28, s. 259–266.
 - 107 **Kuang, C. – Quann, K. – Liman, A. K., et al.**: A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab. *Clin Case Rep*, 2020, 8, s. 1984–1987.
 - 108 **Milani, P. – Basset, M. – Curci, P., et al.**: Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. *Blood Adv*, 2020, 4, s. 1321–1324.
 - 109 **Minařík, J. – Ščudla, V. – Tichý, T., et al.**: Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. *Leuk Lymphoma*, 2012, 53, s. 330–331.
 - 110 **Minařík, J. – Tichý, T. – Pika, T., et al.**: Léčba bortezomibem u pacientů s onemocněním z depozice lehkých řetězců imunoglobulinu. *Vnitř Lék*, 2014, 60, s. 821–826.
 - 111 **Torrebalba, J. – Gattinoni, J. – Hendricks, A. R.**: Proliferative glomerulonephritis with monoclonal immunoglobulin G lambda deposits: report of the first pediatric case. *Case Rep Nephrol Dial*, 2018, 8, s. 70–75.
 - 112 **Tovar, N. – Cibeira, M. T. – Rosinol, L., et al.**: Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. *Eur J Haematol*, 2012, 89, s. 340–344.
 - 113 **Wiklik-Dziadek, M. – Jaworek-Troć, J. – Jurczyszyn, A.**: Amyloidosis, extramedullary plasmacytoma, and light chain deposition disease: impressive results of daratumumab therapy. *Pol Arch Intern Med*, 2021, 131, s. 297–298.
 - 114 **Zand, L. – Rajkumar, S. V. – Leung, N., et al.**: Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits. *J Am Soc Nephrol*, 2021, 32, s. 1163–1173.
 - 115 **Rahbari, E. – Barreca, A. – Nicolino, B., et al.**: PGNMID and anti-CD38 monoclonal antibody: a therapeutic challenge. *G Ital Nefrol*, 2022, 39, s. 2022-vol11.
 - 116 **Kastritis, E. – Theodorakou, F. – Roussou, M., et al.**: Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. *Br J Haematol*, 2021, 193, s. 113–118.
 - 117 **Gozzetti, A. – Guarneri, A. – Zamagni, E., et al.**: Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. *Am J Hematol*, 2022, 97, s. 877–884.
 - 118 **Miki, K. – Shimamura, Y. – Maeda, T., et al.**: Successful renal recovery from multiple myeloma-associated crystalline light chain cast nephropathy and accompanying acute kidney injury with early use of bortezomib-based therapy: a case report and literature review. *CEN Case Rep*, 2023, 12, s. 56–62.
 - 119 **Tsuyuki, T. – Uramatsu, T. – Shimizu, M., et al.**: Improvement of light chain proximal tubulopathy without crystals in IgGλ-type monoclonal gammopathy of undetermined significance using bortezomib and dexamethasone: a case report. *Intern Med*, 12. 7. 2023.
 - 120 **Cheng, S. – Huang, L. – Fan, W., et al.**: Efficacy of novel agents in patients with nephropathy associated with POEMS syndrome. *Int Urol Nephrol*, 2022, 54, s. 2317–2325.
 - 121 **Janoušek, R. – Krajina, A. – Renc, O., et al.**: Efekt jódové kontrastní látky na reziduální ledvině funkci u hemodialyzovaných nemocných – prospektivní studie. *Česká radiologie*, 2008, 62, s. 329–333.
 - 122 **Janoušek, R. – Krajina, A.**: Nefropatie indukovaná aplikací jódové kontrastní látky (kontrastní nefropatie). *Česká radiologie*, 2005, 59, s. 128–132.
 - 123 **Spitzer, D. – Spitzerová, O.**: Méně známé závažné forenzní souvislosti aplikace jódové či gadoliniové kontrastní látky. *Česká radiologie*, 2010, 64, suppl. 1, s. 61–62.
 - 124 **Leung, N. – Bridoux, F. – Batuman, V., et al.**: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nat Rev Nephrol*, 2019, 15, s. 45–59.

Místo chemoterapie v léčbě metastatického hormonálně závislého karcinomu prsu

prof. MUDr. Petra Tesařová, CSc. Ústav radiační onkologie FNB a 1. LF UK a Onkologická klinika VFN a 1. LF UK, Praha

- 1 **Petrelli, F. – Dottorini, L. – Di Menna, G., et al.**: The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. *Breast*, 2023, 71, s. 138–142.
- 2 **Goyal, R. K. – Chen, H. – Abughosh, S. M., et al.**: Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER-Medicare

population-based study. *Cancer*, 2023, 129, s. 1051–1063.

- 3 **Benvenuti, C. – Gaudio, M. – Jacobs, F., et al.:** Clinical review on the management of breast cancer visceral crisis. *Biomedicines*, 2023, 11, s. 1083.
- 4 **Lüftner, D.:** New treatment options for hormone receptor positive breast cancer in 2023. *Curr Opin Obstet Gynecol*, 2023, 35, s. 62–66.
- 5 **Huppert, L. A. – Gumusay, O. – Idossa, D. – Rugo, H. S.:** Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. *CA Cancer J Clin*, 2023, 73, s. 480–515.
- 6 **Mittal, A. – Molto Valiente, C. – Tamimi, F., et al.:** Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer. *Cancers*, 2023, 15, s. 2015.
- 7 **Giuliano, M. – Schettini, F. – Rognoni, C., et al.:** Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. *Lancet Oncol*, 2019, 20, s. 1360–1369.
- 8 **Cortes, J. – O'Shaughnessy, J. – Loesch, D., et al.:** EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*, 2011, 377, s. 914–23.
- 9 **Garrone, O. – Miraglio, E. – Vandone, A. M., et al.:** Eribulin in advanced breast cancer: safety, efficacy and new perspectives. *Future Oncol*, 2017, 13, s. 2759–2769.
- 10 **Tanni, K. A. – Truong, C. B. – Johnson, B. S. – Qian, J.:** Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis. *Crit Rev Oncol Hematol*, 2021, 163, s. 103375.
- 11 **Goyal, R. K. – Zhang, J. – Davis, K. L., et al.:** Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior PI3K inhibitor therapy for metastatic breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 6–10. 12. 2022, San Antonio, TX. Philadelphia (PA): AACR; *Cancer Res*, 2023, 83, suppl. 5, abstrakt P1-03-03.
- 12 **Real-world Treatment Patterns and Clinical Outcomes in Patients Treated With Eribulin After Prior Immunotherapy (IO) or Antibody-Drug Conjugate (ADC) for Metastatic Breast Cancer.** Breast Cancer Conference* Abstracts Supplement 39th Annual Miami Breast Cancer Conference* – ročník 36, suppl. 3.
- 13 **Mougalian, S. S. – Feinberg, B. A. – Wang, E., et al.:** Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy. *Future Oncol*, 2019, 15, s. 3935–3944.

- 14 **Kazmi, S. – Chatterjee, D. – Raju, D., et al.:** Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. *Breast Cancer Res Treat*, 2020, 184, s. 559–565.
- 15 **Li, W. – Wang, H. – Li, X.:** Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials. *Curr Med Res Opin*, 2013, 29, s. 1443–1452.
- 16 **Li, W. – Wang, H. – Li, X.:** Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials. *Curr Med Res Opin*, 2013, 29, s. 1443–452.
- 17 **Egger, S. J. – Willson, M. L. – Morgan, J., et al.:** Platinum-containing regimens for metastatic breast cancer. *Cochrane Database Syst Rev*, 2017, 6, CD003374.
- 18 **Rugo, H. S. – Bardia, A. – Tolaney, S. M., et al.:** TROPICS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2– metastatic breast cancer. *Future Oncol*, 2020, 16, s. 705–715.
- 19 **Makhlin, I. – DeMichele, A.:** Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. *Cell Rep Med*, 2022, 3, s. 100668.
- 20 **Dostupné z:** <https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline/er-positive-her2-negative-breast-cancer>, vyhledáno 14. 10. 2023.

Léčba triple negativního karcinomu prsu sacituzumab govitecanem – kazuistika

MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno

- 1 **Wolff, A. C., et al.:** Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists clinical practice guideline update. *J Clin Oncol*, 2013, 31, s. 3997–4013.
- 2 **Dent, R., et al.:** Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*, 2007, 13, s. 4429–4434.
- 3 **Lin, N. U., et al.:** Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. *Cancer*, 2008, 113, s. 2638–2645.
- 4 **Puri, A. – Reddy, T. P. – Patel, T. A., et al.:** Metastatic triple-negative breast cancer: Established and emerging treatments. *Breast J*, 2020, 26, s. 1793–1796.
- 5 **Schmid, P. – Adams, S. – Rugo, H. S., et al.:** Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*, 2018, 379, s. 2108–2121.

- 6 **Trerotola, M. – Cantanelli, P. – Guerra, E., et al.:** Upregulation of Trop-2 quantitatively stimulates human cancer growth. *Oncogene*, 2013, 32, s. 222–233.
- 7 **Bardia, A. – Hurvitz, S. A. – Tolaney, S. M., et al.:** Sacituzumab govitecan in metastatic triple negative breast cancer. *N Engl J Med*, 2021, 384, s. 1529–1541.

HER2 low nádory prsu a přístup k nim

MUDr. Zuzana Bielčíková, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

- 1 **Wolff, A. C. – Hammond, M. E. H. – Allison, K. H., et al.:** Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *J Clin Oncol*, 2018, 36, s. 2105–2122.
- 2 **Fehrenbacher, L. – Cecchini, R. S. – Geyer, C. E. Jr., et al.:** NSABP B-47/NRG Oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. *J Clin Oncol*, 2020, 38, s. 444–453.
- 3 **Burris, H. A. 3rd. – Rugo, H. S. – Vukelja, S. J., et al.:** Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. *J Clin Oncol*, 2011, 29, s. 398–405.
- 4 **Eiger, D. – Agostinetti, E. – Saúde-Condé, R., et al.:** The exciting new field of HER2-low breast cancer treatment. *Cancers*, 2021, 13, s. 1015.
- 5 **Tarantino, P. – Hamilton, E. – Tolaney, S. M., et al.:** HER2-low breast cancer: pathological and clinical landscape. *J Clin Oncol*, 2020, 38, s. 1951–1962.
- 6 **Ferraro, E. – Drago, J. Z. – Modi, S.:** Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. *Breast Cancer Res*, 2021, 23, s. 84.
- 7 **Lai, H. Z. – Han, J. R. – Fu, X., et al.:** Targeted approaches to HER2-low breast cancer: current practice and future directions. *Cancers*, 2022, 14, s. 3774.
- 8 **Modi, S. – Park, H. – Murthy, R. K., et al.:** Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. *J Clin Oncol*, 2020, 38, s. 1887–1896.
- 9 **Dieras, V. – Deluche, E. – Lusque, A., et al.:** Abstract PD8-02: Trastuzumab deruxtecan for advanced breast cancer patients, regardless of HER2 status: A phase II study with biomarkers analysis (DAISY). *Cancer Res*, 2022, 82, suppl. 4, PD8-02.
- 10 **Tarantino, P. – Curigliano, G. – Tolaney, S. M.:** Navigating the HER2-low paradigm in breast oncology: new standards, future horizons. *Cancer Discov*, 2022, 12, s. 2026–2030.
- 11 **Wolff, A. C. – Somerfield, M. R. – Dowsett, M., et al.:** Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update. *Arch Pathol Lab Med*, 2023, dostupné z: <https://doi.org/10.5858/arpa.2023-0950-SA>, vyhledáno 2. 8. 2023.
- 12 **Dundr, P.:** Testování HER2 pozitivita – současnost a budoucnost. *Breast Cancer News*, 2022, 1.
- 13 **Tarantino, P. – Jin, Q. – Tayob, N., et al.:** Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. *JAMA Oncol*, 2022, 8, s. 1177–1183.
- 14 **Tarantino, P. – Gandini, S. – Nicolò, E., et al.:** Evolution of low HER2 expression between early and advanced-stage breast cancer. *Eur J Cancer*, 2022, 163, s. 35–43.
- 15 **Kensler, K. H. – Sankar, V. N. – Wang, J., et al.:** PAM50 molecular intrinsic subtypes in the nurses' health study cohorts. *Cancer Epidemiol Biomarkers Prev*, 2019, 28, s. 798–806.
- 16 **Harbeck, N. – Modi, S. – Jacot, W., et al.:** Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: subgroup analyses from DESTINY-Breast04. *Cancer Research*, 2023, 83, suppl. 5, abstrakt P1-11-01.
- 17 **Mo, H. – Renna, C. E. – Moore, H. C. F., et al.:** Real-world outcomes of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors. *Clin Breast Cancer*, 2022, 22, s. 143–148.
- 18 **Schmid, P. – Rugo, H. S. – Adams, S., et al.:** Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Update efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2020, 21, s. 44–59.
- 19 **Miles, D. W. – Diéras, V. – Cortés, J., et al.:** First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. *Ann Oncol*, 2013, 24, s. 2773–2780.
- 20 **Modi, S. – Jacot, W. – Yamashita, T., et al.:** DESTINY-Breast04 Trial Investigators: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med*, 2022, 387, s. 9–20.
- 21 **Popović, M. – Silovski, T. – Kržič, M., et al.:** HER2 low breast cancer:

- a new subtype or a Trojan for cytotoxic drug delivery? *Int J Mol Sci*, 2023, 24, s. 8206.
- 22 **Saura Manich, C. – O'Shaughnessy, J. – Aftimos, P. G., et al.:** LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing [vc]-trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. *Ann Oncol*, 2021, 32, s. S1288.
- 23 **Banerji, U. – van Herpen, C. M. L. – Saura Manich, C., et al.:** Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study. *Lancet Oncol*, 2019, 20, s. 1124–1135.
- 24 **Shi, F. – Liu, Y. – Zhou, X., et al.:** Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy. *Drug Deliv*, 2022, 29, s. 1335–1344.
- 25 **Jiang, Z. – Sun, T. – Wang, X., et al.:** A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer. *J Clin Oncol*, 2022, 40, suppl. 16, s. 1102.
- 26 **Murthy, R. K. – Loi, S. – Okines, A., et al.:** Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*, 2020, 382, s. 597–609.
- 27 **Jerusalem, G. – Park, Y. H. – Yamashita, T., et al.:** Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis. *Cancer Discov*, 2022, 12, s. 2754–2762.
- 28 **Cortés, J. – Kim, S. B. – Chung, W. P., et al.:** DESTINY-Breast03 Trial Investigators: Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *N Engl J Med*, 2022, 386, s. 1143–1154.
- 29 **Jacobson, A.:** Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases. *Oncologist*, 2022, 27, suppl. 1, s. S3–S4.
- 30 **Bartsch, R. – Berghoff, A. S. – Furtner, J., et al.:** Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. *Nat Med*, 2022, 28, s. 1840–1847.

Nové postavení inhibitorů CDK4/6 v léčbě časného karcinomu prsu

MUDr. Vlastimila Čmejlová Onkologická klinika 2. LF UK a FN v Motole, Praha

- 1 Mayer, E. L. – Gnant, M. I. – DeMichele, A., et al.: PALLAS: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. *Ann Oncol*, 2020, 31, suppl. 4, s. S1142e215.
- 2 Gnant, M. – Dueck, A. C. – Frantal, S., et al.: Adjuvant palbociclib for early breast cancer: the PALLA Strial results (ABCSG-42/AFT-05/BIG-14-03). *J Clin Oncol*, 2022, 40, s. 282–293.
- 3 Loibl, S. – Marmé, F. – Martin, M., et al.: Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer – the Penelope-B trial. *J Clin Oncol*, 2021, 39, s. 1518–1530.
- 4 Johnston, S., et al.: Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2023, 24, s. 77–90.
- 5 Slamon, D. J. – Fasching, P. A. – Patel, R., et al.: NATALEE: phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). *J Clin Oncol*, 2019, 37, suppl. 15.
- 6 Adding Ribociclib to Endocrine Therapy May Reduce Recurrence Risk in Patients With Hormone Receptor-Positive, HER2-Negative Early-Stage Breast Cancer. By The ASCO Post Staff. Dostupné z: <https://ascopost.com/news/june-2023/adding-ribociclib-to-endocrine-therapy-may-reduce-recurrence-risk-in-patients-with-hr-positive-her2-negative-early-stage-breast-cancer/>, vyhledáno 6. 8. 2023.

Léčba nádorů jícnu a gastroezofageální junkce

MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 Modrá kniha ČOS ČLS JEP pro rok 2023 – aktuální vydání. Dostupné z: www.linkos.cz.
- 2 Obermannová, R. – Alsina, M. – Cervantes, A., et al.: Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2022, 33, s. 992–1004.
- 3 Dundr, P. – Matěj, R. – Rýska, A.: Doporučení pro testování PD-L1: metodika testování a reportování výsledků Verze_3 (13. 5. 2022). *Cesk Patol*, 2021, 57, s. 179–180.
- 4 UICC: TNM Klasifikace zhoubných novotvarů – 8. vydání. 2017. Dostupné z: https://www.uzis.cz/sites/default/files/knihovna/TNM_8_Prezentace_Klasifikace_zhoubnych_novotvaru.pdf, vyhledáno 5. 9. 2023.

Moderní léčba nádorů žlučníku a žlučových cest se zaměřením na imunoterapii

MUDr. Michal Eid Interní hematologická a onkologická klinika FN Brno a LF MU, Brno

- 1 Oh, D.-Y. – He, A. R. – Qin, S., et al.: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. *NEJM Evid*, 2022, 1.
- 2 Kelley, R. K. – Ueno, M. – Yoo, C., et al.: Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2023, 401, s. 1853–1865.
- 3 Chiorean, E. G. – Chiaro, M. D. – Tempero, M. A., et al.: Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 2023, 21, s. 753–782.
- 4 Primrose, J. N. – Fox, R. P. – Palmer, D. H., et al.: Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. *Lancet Oncol*, 2019, 20, s. 663–673.
- 5 Shroff, R. T. – Kennedy, E. B. – Bachini, M., et al.: Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. *J Clin Oncol*, 2019, 37, s. 1015–1027.
- 6 Edeline, J. – Lamarca, A. – McNamara, M. G., et al.: Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. *Cancer Treat Rev*, 2021, 99, s. 102258.
- 7 Valle, J. – Wasan, H. – Palmer, D. H., et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med*, 2010, 362, s. 1273–1281.
- 8 Sahai, V. – Griffith, K. A. – Beg, M. S., et al.: A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BiIT-01. *Cancer*, 2022, 128, s. 3523–3530.
- 9 Bailly, C. – Thuru, X. – Quesnel, B.: Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. *NAR Cancer*, 2020, 2, zcaa002.
- 10 Marabelle, A. – Le, D. T. – Ascierto, P. A., et al.: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol*, 2020, 38, s. 1–10.
- 11 Marabelle, A. – Fakih, M. – Lopez, J., et al.: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol*, 2020, 21, s. 1353–1365.
- 12 Klein, O. – Kee, D. – Nagrial, A., et al.: Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers. *JAMA Oncol*, 2020, 6, s. 1405–1409.
- 13 Ioka, T. – Ueno, M. – Oh, D. Y., et al.: Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). *JCO*, 2019, 37, suppl. 4, s. 387–387.
- 14 Lo, J. H. – Agarwal, R. – Goff, L. W., et al.: Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies. *Cancers*, 2023, 15, s. 3312.
- 15 Lamarca, A. – Palmer, D. H. – Wasan, H. S., et al.: Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. *Lancet Oncol*, 2021, 22, s. 690–701.
- 16 Abou-Alfa, G. K. – Macarulla, T. – Javle, M. M., et al.: Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2020, 21, s. 796–807.
- 17 Zhu, A. X. – Macarulla, T. – Javle, M. M., et al.: Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. *JAMA Oncol*, 2021, 7, s. 1669–1677.
- 18 Abou-Alfa, G. K. – Sahai, V. – Hollebecque, A., et al.: Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. *Lancet Oncol*, 2020, 21, s. 671–684.
- 19 Javle, M. – Roychowdhury, S. – Kelley, R. K., et al.: Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. *Lancet Gastroenterol Hepatol*, 2021, 6, s. 803–815.
- 20 Goyal, L. – Meric-Bernstam, F. – Hollebecque, A., et al.: Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. *N Engl J Med*, 2023, 388, s. 228–239.
- 21 Subbiah, V. – Sahai, V. – Maglic, D., et al.: RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. *Cancer Discov*, 2023, CD-23-0475.
- 22 Javle, M. – Borad, M. J. – Azad, N. S., et al.: Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (My Pathway): a multicentre, open-label, phase 2a, multiple basket study. *Lancet Oncol*, 2021, 22, s. 1290–1300.
- 23 Lee, C. K. – Chon, H. J. – Cheon, J., et al.: Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). *Lancet Gastroenterol Hepatol*, 2023, 8, s. 56–65.
- 24 Nakamura, Y. – Mizuno, N. – Sunakawa, Y., et al.: Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGTUC-019): A phase 2 basket study. *JCO*, 2023, 41, suppl. 16, s. 4007–4007.
- 25 Harding, J. J. – Fan, J. – Oh, D. Y., et al.: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. *Lancet Oncol*, 2023, 24, s. 772–782.
- 26 Subbiah, V. – Kreitman, R. J. – Wainberg, Z. A., et al.: Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. *Nat Med*, 2023, 29, s. 1103–1112.

Buprenorfin v onkologické paliativní péči

MUDr. Ondřej Sláma, Ph.D. Centrum paliativní péče, Masarykův onkologický ústav, Brno

- 1 Sláma, O., et al.: Farmakoterapie nádorové bolesti. In: *Modrá kniha české onkologické společnosti*, 2023, 29. vydání. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/29-33-farmakoterapie-nadorove-bolesti/>, vyhledáno 13. 7. 2023.
- 2 Gudlin, J. – Fudin, J.: A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. *Pain Ther*, 2020, 9, s. 41–54.
- 3 Vránová, V.: Nová transdermální forma nízkodávkovaného buprenorfinu. *Bolest*, 2023, 2, s. 61–63.
- 4 Pergolizzi, J. V. Jr. – Mercadante, S. – Echaburu, A. V., et al.: The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. *Curr Med Res Opin*, 2009, 25, s. 1517–1528.
- 5 Degnan, M. – Mousa, S. A.: A narrative review of buprenorphine in adult cancer pain. *Expert Rev Clin Pharmacol*, 2020, 13, s. 1159–1167.
- 6 Hall, S. – Gallagher, R. M. – Gracely, E., et al.: The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose. *Pain Med*, 2003, 4, s. 125–134.
- 7 Chwistek, M. – Sherry, D. – Kinczewski, L., et al.: Should buprenorphine be considered a first-line opioid for the treatment of moderate to severe cancer pain? *J Pain Symptom Manag*, 2023, S0885-3924(23)00566-3.

Karcinom plic na ASCO 2023

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- Osarogiagbon, R. U. – Yang, P. Ch. – Sequist, L. V.: Expanding the reach and grasp of lung cancer screening. *Am Soc Clin Oncol Educ Book*, 2023, 43, DOI: 10.1200/EDBK_389958.
- O'Reilly, D. – Botticella, A. – Barry, S., et al.: Treatment decisions for resectable non-small-cell lung cancer: Balancing less with more? *Am Soc Clin Oncol Educ Book*, 2023, 43, DOI: 10.1200/EDBK_389950.
- Herbst, R. S. – Wu, Y. L. – John, T., et al.: Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. *J Clin Oncol*, 2023, 41, s. 1830–1840.
- Wakelee, H. – Liberman, M. – Kato, T., et al. for the KEYNOTE-671 Investigators: Perioperative pembrolizumab for early-stage non-small-cell lung cancer. *N Engl J Med*, 2023, 389, s. 491–503.
- Heymach, J. V. – Harpole, D. – Mitsudomi, T., et al.: AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Prezentace na 2023 AACR Annual Meeting; 14.–19. 4. 2023, Orlando, FL, abstrakt CT005.
- Lu, S. – Wu, L. – Zhang, W., et al.: Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III NEOTORCH study. *J Clin Oncol*, 2023, 51, s. 36 (suppl., abstrakt 425126).
- Rosner, S. – Valdivia, A. – Hoe, H. J., et al.: Antibody-drug conjugates for lung cancer: payloads and progress. *Am Soc Clin Oncol Educ Book*, 2023, 43, DOI: https://doi.org/10.1200/EDBK_389968.
- Tsuboi, M. – Herbst, R. A., et al.: Overall survival with osimertinib in resected EGFR-mutated NSCLC. *N Engl J Med*, 2023, DOI: 10.1056/NEJMoa2304594.

Současné postavení monoterapie anti-PD-1 protilátkami v léčbě pokročilého melanomu

MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika 1. LF UK a Všeobecná fakultní nemocnice, Praha

- Joseph, R. W. – Liu, F. X. – Shillington, A. C., et al.: Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. *Qual Life Res*, 2020, 29, s. 2651–2660.
- Hamid, O. – Robert, C. – Daud, A., et al.: Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE 001. *Ann Oncol*, 2019, 30, s. 582–588.
- Robert, C. – Carlino, M. S. – McNeil, C., et al.: 7-year follow-up of KEYNOTE-006: pembrolizumab versus ipilimumab in advanced melanoma. *J Clin Oncol*, 2023, JCO2201599.
- Hodi, F. S. – Chiarion-Sileni, V. – Lewis, K. D., et al.: Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. Abstrakt 9522. Dostupné z: <https://meetings.asco.org/2022-asco-annual-meeting/14397?presentation=210314#210314>, vyhledáno 8. 8. 2023.
- Iacono, D. – Vitale, M. G. – Basile, D.: Immunotherapy for older patients with melanoma: From darkness to light? *Pigment Cell Melanoma Res*, 2021, 34, s. 550–563.
- Foo, T. – Tapia Rico, G. – Roberts-Thomson, R.: Immunotherapy in older patients with advanced melanoma: a review of the current evidence. *Drugs Aging*, 2020, 37, s. 411–423.
- Weiss, S. A. – Kluger, H.: CheckMate-067: raising the bar for the next decade in oncology. *J Clin Oncol*, 2022, 40, s. 111–113.
- Robert, C. – Hwu, W. J. – Hamid, O., et al.: Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. *Eur J Cancer*, 2021, 144, s. 182–191.
- Ascierto, P. A. – Mandalà, M. – Ferrucci, P. F.: Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. *J Clin Oncol*, 2023, 41, s. 212–221.
- Atkins, M. B. – Lee, S. J. – Chmielowski, B.: Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. *J Clin Oncol*, 2023, 41, s. 186–197.
- Wolchok, J. D. – Chiarion-Sileni, V. – Gonzalez, R.: Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. *J Clin Oncol*, 2022, 40, s. 127–137.

Přehled nejvýznamnějších změn v 5. vydání WHO klasifikace lymfoidních nádorů

MUDr. Vít Campr Ústav patologie a molekulární medicíny 2. LF UK a FN v Motole, Praha

- Alaggio, R., et al.: *The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia*. Dostupné z: <https://doi.org/10.1038/s41375-022-01620-2>, vyhledáno 13. 7. 2023.
- Campo, E., et al.: The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood*, 1922, 140, s. 1229–1253.

Imunoterapie kožních lymfomů

MUDr. Kamila Polgárová, Ph.D. Interní klinika – klinika hematologie, 1. LF UK a VFN, Praha

- Polgárová, K. – Polívka, J. – Kodet, O. – Klenner, P. – Trněný, M.: Retrospective analysis of 118 patients with cutaneous T-cell lymphomas: a single-center experience. *Front Oncol*, 2022, 12, s. 884091.
- Lundin, J. – Hagberg, H. – Repp, R., et al.: Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. *Blood*, 2003, 101, s. 4267–4272.
- Bernengo, M. G. – Quaglino, P. – Comessatti, A., et al.: Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. *Haematologica*, 2007, 92, s. 784–794.
- Reifs, C. M. A. – Salido-Vallejo, R. – Garnacho-Saucedo, G. M., et al.: Alemtuzumab in refractory Sézary syndrome. *An Bras Dermatol*, 2016, 91, s. 642–644.
- Tobinai, K. – Takahashi, T. – Akinaga, S.: Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. *Curr Hematol Malig Rep*, 2012, 7, s. 235–240.
- Vermeer, M. H. – Dukers, D. F. – ten Berge, R. L., et al.: Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease. *Mod Pathol*, 2002, 15, s. 838–844.
- Duvic, M. – Pinter-Brown, L. C. – Foss, F. M., et al.: Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. *Blood*, 2015, 125, s. 1883–1889.
- Kim, Y. H. – Bagot, M. – Pinter-Brown, L., et al.: Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *Lancet Oncol*, 2018, 19, s. 1192–1204.
- Cowan, R. A. – Scarisbrick, J. J. – Zinzani, P. L., et al.: Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. *J Eur Acad Dermatol Venereol*, 2021, 35, s. 2225–2238.
- Beylot-Barry, M. – Quereux, G. – Nardin, C., et al.: Effectiveness of mogamulizumab in patients with mycosis fungoides or Sézary syndrome: a multicentre, retrospective, real-world French study. *J Eur Acad Dermatol Venereol*, 27. 4. 2023, doi: 10.1111/jdv.19134.
- Querfeld, C.: Mechanisms of resistance to mogamulizumab. *Blood*, 2022, 139, s. 3674–3676.
- Rocuzzo, G. – Giordano, S. – Fava, P., et al.: Immune check point inhibitors in primary cutaneous T-cell lymphomas: biologic rationale, clinical results and future perspectives. *Front Oncol*, 2021, 11, s. 733770.
- Khodadoust, M. S. – Rook, A. H. – Porcu, P., et al.: Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. *J Clin Oncol*, 2020, 38, s. 20–28.
- Roberts, N. – Lister, J. – Bannani, N. N., et al.: Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL): preliminary results from the Embolden Trial. *Blood*, 2022, 140, suppl. 1, s. 9425–9426.
- Bar-Sela, G. – Bergman, R.: Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma. *JAAD Case Rep*, 2015, 1, s. 99–100.
- Stadler, R.: Inhibition of the CD47-SIRPα axis by TTI-621 to treat relapsed or refractory mycosis fungoides or Sézary syndrome. *Lancet Haematol*, 2021, 8, s. e779–e781.
- Battistella, M. – Leboeuf, C. – Ram-Wolf, C., et al.: KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. *Blood*, 2017, 130, s. 2900–2902.
- Bagot, M. – Porcu, P. – Marie-Cardine, A., et al.: IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. *Lancet Oncol*, 2019, 20, s. 1160–1170.
- Kim, Y. H. – Bagot, M. – Ortiz-Romero, P. L., et al.: Lacutamab in patients with advanced mycosis fungoides (MF): efficacy results according to updated lymph node (LN) classification in the tellomak study. *Hematol Oncol*, 2023, 41, s. 196–197.
- Prince, H. M. – Kim, Y. H. – Horwitz, S. M., et al.: Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. *Lancet*, 2017, 390, s. 555–566.
- Lewis, D. J. – Haun, P. L. – Samimi, S. S., et al.: Brentuximab vedotin for relapsed or refractory Sézary syndrome. *JAMA dermatology*, 2021, 157, s. 317–321.
- Edinger, J. T. – Clark, B. Z. – Pucevich, B. E., et al.: CD30 expression and proliferative fraction in nontransformed mycosis fungoides. *Am J Surg Pathol*, 2009, 33, s. 1860–1868.
- Kim, Y. H. – Prince, H. M. – Whittaker, S., et al.: Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. *Eur J Cancer*, 2021, 148, s. 411–421.
- Polgárová, K. – Otáhal, P. – Šálek, C., et al.: Chimeric antigen receptor based cellular therapy for treatment of T-cell malignancies. *Front Oncol*, 2022, 12, s. 876758.
- Peiffer, L. – Gambichler, T. – Buus, T. B., et al.: Phenotypic plasticity of malignant T cells in blood and skin of a Sézary syndrome patient revealed by single cell transcriptomics. *Front Oncol*, 2023, 13, s. 1090592.
- Scarfò, I. – Frigault, M. J. – Maus, M. V.: CAR-based approaches to cutaneous T-cell lymphoma. *Front Oncol*, 2019, 9, s. 259.
- Ramos, C. A. – Ballard, B. – Zhang, H., et al.: Clinical and immunological responses after CD30-specific chimeric antigen receptor-directed lymphocytes. *J Clin Invest*, 2017, 127, s. 3462–3471.
- To, V. – Evtimov, V. J. – Jenkin, G., et al.: CAR-T cell development for cutaneous T cell lymphoma: current limitations and potential treatment strategies. *Front Immunol*, 2022, doi.org/10.3389/fimmu.2022.968395.

Imunoterapie u klasického Hodgkinova lymfomu

MUDr. Juraj Ďuraš | MUDr. Michal Kaščák | prof. MUDr. Roman Hájek, CSc. Klinika hematookologie, FN Ostrava; Klinika hematookologie, Lékařská fakulta, Ostravská univerzita

- Bröckelmann, P. J. – Sasse, S. – Engert, A.: Balancing risk and benefit in early-stage classical Hodgkin lymphoma. *Blood*, 2018, 131, s. 1666–1678.
- Spinner, M. A. – Advani, R. H.: Risk-adapted therapy for advanced-stage Hodgkin lymphoma. *Hematology Am Soc Hematol Educ Program*, 2018, 2018, s. 200–206.
- Evens, A. M. – Carter, J. – Loh, K. P., et al.: Management of older Hodgkin lymphoma patients. *Hematology Am Soc Hematol Educ Program*, 2019, 2019, s. 233–242.
- Broccoli, A. – Zinzani, P. L.: The role of transplantation in Hodgkin lymphoma. *Br J Haematol*, 2019, 184, s. 93–104.
- Kewalramani, T. – Nimer, S. D. – Zelenetz, A. D., et al.: Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. *Bone Marrow Transplant*, 2003, 32, s. 673–679.
- Moskowitz, A. J. – Perales, M. A. – Kewalramani, T., et al.: Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. *Br J Haematol*, 2009, 146, s. 158–163.
- Böll, B. – Goergen, H. – Arndt, N., et al.: Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. *JCO*, 2013, 31, s. 4431–4437.
- Chen, R. – Gopal, A. K. – Smith, S. E., et al.: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. *Blood*, 2016, 128, s. 1562–1566.
- Younes, A. – Gopal, A. K. – Smith, S. E., et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *JCO*, 2012, 30, s. 2183–2189.
- Moskowitz, C. H. – Nademanee, A. – Masszi, T., et al.: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2015, 385, s. 1853–1862.
- Moskowitz, C. H. – Walewski, J. – Nademanee, A., et al.: Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. *Blood*, 2018, 132, s. 2639–2642.
- Moskowitz, A. J. – Yahalom, J. – Kewalramani, T., et al.: Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *Blood*, 2010, 116, s. 4934–4937.
- Moskowitz, C. H. – Matasar, M. J. – Zelenetz, A. D., et al.: Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood*, 2012, 119, s. 1665–1670.
- Mocikova, H. – Pytlík, R. – Markova, J., et al.: Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. *Leuk Lymphoma*, 2011, 52, s. 1668–1674.
- Akhtar, S. – Al-Sugair, A. S. – Abouzied, M., et al.: Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. *Bone Marrow Transplant*, 2013, 48, s. 1530–1536.
- Driessen, J. – Tonino, S. H. – Moskowitz, A. J., et al.: How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. *Hematology Am Soc Hematol Educ Program*, 2021, 2021, s. 240–246.
- Vassilakopoulos, T. P. – Asimakopoulos, J. V. – Konstantopoulos, K., et al.: Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. *Ther Adv Hematol*, 2020, 11, 204062072090291.
- Stamatoullas, A. – Ghesquière, H. – Feugier, P., et al.: Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. *Leuk Lymphoma*, 2022, 63, s. 3063–3071.
- Lynch, R. C. – Cassaday, R. D. – Smith, S. D., et al.: Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. *Lancet Haematol*, 2021, 8, s. e562–e571.
- Moskowitz, A. J. – Schöder, H. – Yahalom, J., et al.: PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. *Lancet Oncol*, 2015, 16, s. 284–292.
- Kersten, M. J. – Driessen, J. – Zijlstra, J. M., et al.: Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. *Haematologica*, 2020, 106, s. 1129–1137.
- García-Sanz, R. – Sureda, A. – De La Cruz, F., et al.: Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term result of a trial by the Spanish GELTAMO Group). *Ann Oncol*, 2019, 30, s. 612–620.
- Abuelgasim, K. A. – Alzahrani, M. – Alsharhan, Y., et al.: Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. *Bone Marrow Transplant*, 2019, 54, s. 1168–1172.
- LaCasce, A. S. – Bociek, R. G. – Sawas, A., et al.: Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. *Blood*, 2018, 132, s. 40–48.
- Straus, D. J. – Długosz-Danecka, M. – Connors, J. M., et al.: Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (EChELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. *Lancet Haematol*, 2021, 8, s. e410–e421.
- Ansell, S. M. – Radford, J. – Connors, J. M., et al.: Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. *N Engl J Med*, 2022, 387, s. 310–320.
- Connors, J. M. – Jurczak, W. – Straus, D. J., et al.: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. *N Engl J Med*, 2018, 378, s. 331–344.
- Borchmann, P. – Moccia, A. A. – Greil, R., et al.: Breccadd is non-inferior to ebeacop in patients with advanced stage classical Hodgkin lymphoma: efficacy results of the GHSG phase III HD21 trial. *Hematol Oncol*, 2023, 41, s. 881–882.
- Borchmann, P. – Moccia, A. – Greil, R., et al.: T002: Treatment related morbidity in patients with classical Hodgkin lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group. *HemaSphere*, 2022, 6, s. 1–2.
- Cheson, B. D. – Bartlett, N. L. – LaPlant, B., et al.: Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. *Lancet Haematol*, 2020, 7, s. e808–e815.
- Armand, P. – Engert, A. – Younes, A., et al.: Nivolumab for relapsed/refractory classical Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II Check Mate 205 trial. *JCO*, 2018, 36, s. 1428–1439.
- Ansell, S. – Bröckelmann, P. – Von Keudell, G., et al.: HL-398: Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). *Clin Lymphoma Myeloma Leuk*, 2021, 21, s. S373–S374.
- Chen, R. – Zinzani, P. L. – Lee, H. J., et al.: Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. *Blood*, 2019, 134, s. 1144–1153.
- Zinzani, P. L. – Lee, H. J. – Armand, P., et al.: Three-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma. *Blood*, 2019, 134, s. 240–240.
- Kuruivilla, J. – Ramchandren, R. – Santoro, A., et al.: Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. *Lancet Oncol*, 2021, 22, s. 512–524.
- Zinzani, P. L. – Ramchandren, R. – Santoro, A., et al.: Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. *Blood Adv*, 2022, 6, s. 590–599.
- Armand, P. – Chen, Y.-B. – Redd, R. A., et al.: PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. *Blood*, 2019, 134, s. 22–29.
- Herrera, A. F. – Chen, L. – Nieto, Y., et al.: Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. *Lancet Haematol*, 2023, 10, s. e14–e23.
- Bryan, L. J. – Casulo, C. – Allen, P. B., et al.: Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classical Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. *JAMA Oncol*, 2023, 9, s. 683.
- Mei, M. G. – Lee, H. J. – Palmer, J. M., et al.: Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. *Blood*, 2022, 139, s. 3605–3616.
- Moskowitz, A. J. – Shah, G. – Schöder, H., et al.: Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. *JCO*, 2021, 39, s. 3109–3117.
- Advani, R. H. – Moskowitz, A. J. – Bartlett, N. L., et al.: Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. *Blood*, 2021, 138, s. 427–438.
- Bröckelmann, P. J. – Goergen, H. – Keller, U., et al.: Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial. *JAMA Oncol*, 2020, 6, s. 872.
- Bröckelmann, P. J. – Bühnen, I. – Meissner, J., et al.: Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial. *JCO*, 2023, 41, s. 1193–1199.
- Ramchandren, R. – Domingo-Domènech, E. – Rueda, A., et al.: Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the Phase II CheckMate 205 study. *JCO*, 2019, 37, s. 1997–2007.
- Torka, P. – Feldman, T. – Savage, K., et al.: Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine, (N-AVD) as frontline therapy in older adults with Hodgkin lymphoma. *Hematol Oncol*, 2023, 41, s. 161–162.
- Lynch, R. C. – Ujjani, C. S. – Poh, C., et al.: Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. *Blood*, 2023, 141, s. 2576–2586.
- Advani, R. H. – Avigdor, A. – Sureda, A., et al.: Pembrolizumab and chemotherapy in newly-diagnosed, early unfavorable or advanced stage classic Hodgkin lymphoma: The phase 2 Keynote-C11 study. *Blood*, 2022, 140, s. 1759–1760.
- Lazarovici, J. – Amorim, S. – Bouabdallah, K., et al.: Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: Niviniho, a Lysa Phase II study. *Blood*, 2021, 138, s. 232–232.
- Herrera, A. F. – LeBlanc, M. L. – Castellino, S. M., et al.: SWOG S1826, a randomized study of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). *JCO*, 2023, 41, s. LBA4–LBA4.
- Ramos, C. A. – Bilgi, M. – Gerken, C. P., et al.: CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). *Blood*, 2018, 132, s. 680–680.
- Grover, N. S. – Park, S. I. – Ivanova, A., et al.: Clinical responses to CAR-CD30-T cells in patients with CD30+ lymphomas relapsed after multiple treatments including brentuximab vedotin. *Blood*, 2018, 132, s. 681–681.
- Ruella, M. – Klichinsky, M. – Kenderian, S. S., et al.: Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells. *Cancer Discovery*, 2017, 7, s. 1154–1167.
- Bollard, C. M. – Gottschalk, S. – Torrano, V., et al.: Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. *JCO*, 2014, 32, s. 798–808.
- Ramos, C. A. – Grover, N. S. – Beaven, A. W., et al.: Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. *JCO*, 2020, 38, s. 3794–3804.
- Ahmed, S. – Mei, M. – Kurtz, D. M., et al.: Combined autologous CD30 CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy (ACTION study). *Hematol Oncol*, 2023, 41, s. 524–525.
- Perriello, V. M. – Martarelli, N. – Gentili, M., et al.: Dual targeting of Hodgkin lymphoma by anti-CD30 CAR-T cells co-transduced with an anti-PDL1 costimulatory receptor to overcome the immunosuppressive microenvironment. *Hematol Oncol*, 2023, 41, s. 99–100.
- Hartmann, F. – Renner, C. – Jung, W., et al.: Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. *Blood*, 1997, 89, s. 2042–2047.
- Reiners, K. S. – Kessler, J. – Sauer, M., et al.: Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. *Mol Ther*, 2013, 21, s. 895–903.
- Wu, J. – Fu, J. – Zhang, M., et al.: AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. *J Hematol Oncol*, 2015, 8, s. 96.
- Oostindie, S. C. – Alemdehy, M. F. – Janmaat, M. L., et al.: Duo-body-CD3xCD30 demonstrates potent anti-tumor activity in pre-clinical models of CD30+ hematologic malignancies. *Blood*, 2022, 140, s. 3153–3154.
- Boyerinas, B. – Jochems, C. – Fantini, M., et al.: Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. *Cancer Immunol Res*, 2015, 3, s. 1148–1157.
- Herrera, A. F. – Burton, C. – Radford, J., et al.: Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. *Blood Adv*, 2021, 5, s. 3387–3396.
- Shi, Y. – Su, H. – Song, Y., et al.: Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. *Lancet Haematol*, 2019, 6, s. e12–e19.
- Song, Y. – Gao, Q. – Zhang, H., et al.: Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis. *Clin Canc Res*, 2022, 28, s. 1147–1156.
- Timmerman, J. – Lavie, D. – Johnson, N. A., et al.: Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory

(R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study. *JCO*, 2022, 40, s. 7545–7545.

67 Carlo-Stella, C. – Ansell, S. – Zinzani, P. L., et al.: S201: Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter,

phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL). *HemaSphere*, 2022, 6, s. 102–103.

Cílená terapie u difuzního velkobuněčného B lymfomu

MUDr. Prokop Vodička | prof. MUDr. Marek Trněný, CSc. I. interní klinika – klinika hematologie, 1. LF UK a VFN, Praha

- 1 Tilly, H. – Morschhauser, F. – Sehn, L. H., et al.: Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 351–363.
- 2 Coiffier, B. – Thieblemont, C. – Van Den Neste, E., et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DL-BCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood*, 2010, 116, s. 2040–2045.
- 3 Alizadeh, A. A. – Eisen, M. B. – Davis, R. E., et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, 2000, 403, s. 503–511.
- 4 Chapuy, B. – Stewart, C. – Dunford, A. J., et al.: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med*, 2018, 24, s. 679–690.
- 5 Schmitz, R. – Wright, G. W. – Huang, D. W., et al.: Genetics and pathogenesis of diffuse large B-cell lymphoma. *N Engl J Med*, 2018, 378, s. 1396–1407.
- 6 Sehn, L. H. – Hertzberg, M. – Opat, S., et al.: Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension. *Blood*, 2020, 136, suppl. 1, s. 17–19.
- 7 Vodička, P. – Benesova, K. – Janikova, A., et al.: Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. *Eur J Haematol*, 2022, 109, s. 162–165.
- 8 Caimi, P. F. – Ai, W. – Alderuccio, J. P., et al.: Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*, 2021, 22, s. 790–800.
- 9 Hutchings, M. – Morschhauser, F. – Iacoboni, G., et al.: Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. *J Clin Oncol*, 2021, 39, s. 1959–1970.
- 10 Locke, F. L. – Miklos, D. B. – Jacobson, C. A., et al.: Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 640–654.
- 11 Bishop, M. R. – Dickinson, M. – Purtil, D., et al.: Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 629–639.
- 12 Kamdar, M. – Solomon, S. R. – Arnason, J., et al.: Lisocabtagene marelucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet*, 2022, 399, s. 2294–2308.
- 13 Wang, M. – Fowler, N. – Wagner-Bartak, N., et al.: Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. *Leukemia*, 2013, 27, s. 1902–1909.
- 14 Nowakowski, G. S. – Chiappella, A. – Gascoyne, R. D., et al.: ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. *J Clin Oncol*, 2021, 39, s. 1317–1328.
- 15 Chamuleau, M. E. D. – Burggraaf, C. N. – Nijland, M., et al.: Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. *Haematologica*, 2020, 105, s. 2805–2812.
- 16 Westin, J. – Nastoupil, L. J. – Fayad, L., et al.: Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. *J Clin Oncol*, 2019, 37, suppl. 15, s. 7508–7508.
- 17 Salles, G. – Duell, J. – Gonzalez Barca, E., et al.: Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. *Lancet Oncol*, 2020, 21, s. 978–988.
- 18 Belada, D. – Kopeckova, K. – Bergua, J. M., et al.: First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL. *J Clin Oncol*, 2021, 39, suppl. 15, s. 7540–7540.
- 19 Vitolo, U. – Nowakowski, G. S. – Burke, J. M., et al.: ABCL-021: FRONT-MIND: a phase III, randomized, double-blind, placebo-controlled study comparing efficacy and safety of tafasitamab + lenalidomide + R-CHOP vs R-CHOP alone for newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). *Clin Lymphoma Myeloma Leuk*, 2021, 21, s. S376–S377.
- 20 Patel, K. – Orlovski, R. Z. – Doucette, K., et al.: TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma. *J Clin Oncol*, 2022, 40, suppl. 16, s. TPS8071–TPS8071.
- 21 Vodička, P. – Klener, P. – Trněný, M.: Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options. *Onco Targets Ther*, 2022, 15, s. 1481–1501.

Cílená terapie u lymfomu z buněk pláště

MUDr. Aleš Obr, Ph.D. Hemato-onkologická klinika LF UP a FN Olomouc

- 1 Alaggio, R. – Amador, C. – Anagnostopoulos, I., et al.: Correction: „The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms”. *Leukemia*, 2022, 36, s. 1720–1748; *Leukemia*, 2023, 37, s. 1944–1951.
- 2 Belada, D. – Trněný, M., a kolektiv autorů Kooperativní lymfomové skupiny: Diagnostické a léčebné postupy u nemocných s maligními lymfomy – XIII (10. tištěné) vydání. Hradec Králové: HK Credit, s.r.o.; 2023. Dostupné z: https://www.lymphoma.cz/_uploads/attachments/KLS_guidelines_brozura_2023_30007_interaktivni_4_1.pdf, vyhledáno 25. 9. 2023.
- 3 Dreyling, M. – Campo, E. – Hermine, O., et al.: Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, suppl. 4, s. iv62–iv71.
- 4 Bernard, M. – Gressin, R. – Lefrère, F., et al.: Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. *Leukemia*, 2001, 15, s. 1785–1791.
- 5 Argatoff, L. H. – Connors, J. M. – Klasa, R. J., et al.: Mantle cell lymphoma: a clinicopathologic study of 80 cases. *Blood*, 1997, 89, s. 2067–2078.
- 6 Belada, D. – Trněný, M., a kolektiv autorů Kooperativní lymfomové skupiny: Diagnostické a léčebné postupy u nemocných s maligními lymfomy – XI. 2020. Dostupné z: https://www.lymphoma.cz/_uploads/attachments/KLS_guidelines_2020_prolinkovana_verze_1.pdf, vyhledáno 25. 9. 2023.
- 7 Hoster, E. – Dreyling, M. – Klapper, W., et al.: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood*, 2008, 111, s. 558–565.
- 8 Hoster, E. – Klapper, W. – Hermine, O., et al.: Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. *JCO*, 2014, 32, s. 1338–1346.
- 9 Hoster, E. – Rosenwald, A. – Berger, F., et al.: Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. *JCO*, 2016, 34, s. 1386–1394.
- 10 Obr, A. – Procházka, V. – Jirkuvová, A., et al.: TP53 mutation and complex karyotype predicts a dismal prognosis in patients with mantle cell lymphoma. *Clin Lymphoma Myeloma Leuk*, 2018, 18, s. 762–768.
- 11 Malarikova, D. – Berkova, A. – Obr, A., et al.: Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. *Cancers*, 2020, 12, s. 2120.
- 12 Obr, A. – Klener, P. – Furst, T., et al.: A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. *BJHaem*, Dostupné z: <https://onlinelibrary.wiley.com/doi/10.1111/bjh.17063>, vyhledáno 25. 9. 2023.
- 13 Delfau-Larue, M. H. – Klapper, W. – Berger, F., et al.: High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. *Blood*, 2015, 126, s. 604–611.
- 14 Hoster, E. – Pott, C.: Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. *Hematology Am Soc Hematol Educ Program*, 2016, 2016, s. 437–445.
- 15 Lakhotia, R. – Melani, C. – Dunleavy, K., et al.: Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. *Blood Adv*, 2022, 6, s. 2667–2680.
- 16 Obr, A. – Procházka, V. – Papajik, T., et al.: Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry. *Leuk Lymphoma*, 2019, 60, s. 748–755.
- 17 Klener, P. – Salek, D. – Pytlík, R., et al.: Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. *Am J Hematol*, 2019, 94, s. E50–E53.
- 18 Hermine, O. – Hoster, E. – Walewski, J., et al.: Addition of high-dose cytarabine to immunotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. *Lancet*, 2016, 388, s. 565–575.
- 19 Eskelund, C. W. – Kolstad, A. – Jerkeman, M., et al.: 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. *Br J Haematol*, 2016, 175, s. 410–418.
- 20 Klener, P. – Fronkova, E. – Belada, D., et al.: Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. *Hematol Oncol*, 2018, 36, s. 110–115.
- 21 Rummel, M. J. – Niederle, N. – Maschmeyer, G., et al.: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*, 2013, 381, s. 1203–1210.
- 22 Obr, A. – Benesova, K. – Janikova, A., et al.: Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. *Ann Hematol*, 2023, 102, s. 107–115.
- 23 McCulloch, R. – Lewis, D. – Crosbie, N., et al.: Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. *Br J Haematol*, 2021, 193, s. 290–298.
- 24 Cencini, E. – Mecacci, B. – Morelli, F., et al.: Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the „RTL” (regional Tuscany lymphoma network). *Am J Blood Res*, 2021, 11, s. 373–383.
- 25 Rule, S. – Dreyling, M. H. – Goy, A., et al.: Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. *Blood*, 2019, 134, suppl. 1, s. 1538, abstrakt 1623.
- 26 Wang, M. L. – Lee, H. – Chuang, H., et al.: Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. *Lancet Oncol*, 2016, 17, s. 48–56.
- 27 Wang, M. – Ramchandren, R. – Chen, R., et al.: Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. *J Hematol Oncol*, 2021, 14, s. 179.
- 28 Le Gouill, S. – Morschhauser, F. – Chiron, D., et al.: Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. *Blood*, 2021, 137, s. 877–887.
- 29 Dreyling, M. – Doorduijn, J. K. – Gine, E., et al.: Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. *Blood*, 2022, 140, suppl. 1, s. 1–3.
- 30 Jain, P. – Zhao, S. – Lee, H. J., et al.: Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma. *J Clin Oncol*, 2022, 40, s. 202–212.
- 31 Wang, M. L. – Jurczak, W. – Jerkeman, M., et al.: Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. *N Engl J Med*, 2022, 386, s. 2482–2494.
- 32 Song, Y. – Zhou, K. – Zou, D., et al.: Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. *Blood*, 2022, 139, s. 3148–3158.
- 33 Wang, M. – Rule, S. – Zinzani, P. L., et al.: Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. *Leukemia*, 2019, 33, s. 2762–2766.
- 34 Kumar, A. – Soumerai, J. D. – Abramson, J. S., et al.: Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen). *Blood*, 2021, 138, suppl. 1, s. 3540–3540.
- 35 Wang, M. – Robak, T. – Maddocks, K. J., et al.: Acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve (TN) mantle cell lymphoma (MCL): 2-year safety and efficacy analysis. *Blood*,

2022, 140, suppl. 1, s. 6477–6479.

36 Wang, M. L. – Jurczak, W. – Zinzani, P. L., et al.: Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. *JCO*, 2023, 41, s. 3988–3997.

37 Trněný, M. – Lamy, T. – Walewski, J., et al.: Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. *Lancet Oncol*, 2016, 17, s. 319–331.

38 Phillips, T. J. – Bond, D. – Takiar, R., et al.: Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. *Blood Adv*, 2023, 7, s. 4518–4527.

39 Ruan, J. – Martin, P. – Shah, B., et al.: Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. *N Engl J Med*, 2015, 373, s. 1835–1844.

40 Robak, T. – Jin, J. – Pylypenko, H., et al.: Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP)

versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. *Lancet Oncol*, 2018, 19, s. 1449–1458.

41 Lamm, W. – Kaufmann, H. – Raderer, M., et al.: Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. *Haematologica*, 2011, 96, s. 1008–1014.

42 Wang, M. – Munoz, J. – Goy, A., et al.: KTE-X19 CART T-cell therapy in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*, 2020, 382, s. 1331–1342.

43 Wang, Y. – Jain, P. – Locke, F. L., et al.: Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CART Consortium. *JCO*, 2023, 41, s. 2594–2606.

44 Phillips, T. J. – Dickinson, M. – Morschhauser, F., et al.: Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. *Blood*, 2022, 140, suppl. 1, s. 178–180.

45 Clausen, M. R. – Lugtenburg, P. – Hutchings, M., et al.: Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. *JCO*, 2021, 39, suppl. 15, s. 7518–7518.

46 Wang, M. L. – Barrientos, J. C. – Furman, R. R., et al.: Zilovetamab vedotin targeting of ROR1 as therapy for lymphoid cancers. October 12, 2021. *NEJM Evid*, 2022, 1.

47 Zinzani, P. L. – Trněný, M. – Ribrag, V., et al.: Parsaclisib, a PI3K inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study. *eClinicalMedicine*, 2023, 62, 102131.

Novinky v klasifikaci myeloidních neoplazií: klasifikace WHO a ICC

RNDr. Monika Beličková, Ph.D. Ústav hematologie a krevní transfuze, Praha

1 Khoury, J. D. – Solary, E. – Abala, O., et al.: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*, 2022, 36, s. 1703–1719.

2 Arber, D. A. – Orazi, A. – Hasserjian, R. P., et al.: International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data. *Blood*, 2022, 140, s. 1200–1228.

3 Arber, D. A. – Orazi, A. – Hasserjian, R. P., et al.: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*, 2016, 127, s. 2391–2405.

4 Taube, F. – Georgij, J. A. – Kramer, M., et al.: CEBPA mutations in 4708 patients with acute myeloid leukemia: Differential impact of bZIP and TAD mutations on outcome. *Blood*, 2022, 139, s. 87–103.

5 Döhner, H. – Wei, A. H. – Appelbaum, F. R., et al.: Diagnosis and management of AML in adults: 2022 recommendations from an

international expert panel on behalf of the ELN. *Blood*, 2022, 140, s. 1345–1377.

6 Greenberg, P. L. – Tuechle, H. – Schanz, J., et al.: Revised international prognostics scoring system for myelodysplastic syndromes. *Blood*, 2012, 120, s. 2454–2465.

7 Bernard, E. T. H. – Greenberg, P. L. – Hasserjian, R. P., et al.: Molecular international prognostic scoring system for myelodysplastic syndromes. *NEJM Evid*, 2022, 1.

Cílená terapie chronické myeloidní leukemie

MUDr. Petra Čičátková | doc. MUDr. Daniela Žáčková, Ph.D. Interní hematologická a onkologická klinika FN Brno a LF MU, Brno

1 Hochhaus, A. – Larson, R. A. – Guilhot, F., et al.: Long-term outcomes of imatinib treatment for chronic myeloid leukemia. *N Engl J Med*, 2017, 379, s. 919–927.

2 Cortes, J. E. – Saglio, G. – Kantarjian, H. M., et al.: Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. *J Clin Oncol*, 2016, 36, s. 2333–2340.

3 Kantarjian, H. M. – Huges, T. P. – Larson, R. A., et al.: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. *Leukemia*, 2021, 35, s. 440–453.

4 Brummendorf, T. H. – Cortes, J. E. – Milojkovic, D., et al.: Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. *Leukemia*, 2022, 36, s. 1825–1833.

5 Cortes, J. E. – Kim, D. W. – Pinilla Ibranz, J., et al.: Ponatinib efficacy and safety in Philadelphia chromosome positive leukemia: final 5 year results of the phase 2 PACE trial. *Blood*, 2018, 132, s. 393–404.

6 Cortes, J. – Deininger, M. W. – Lomaia, E., et al.: Three-year update from the optic trial: a dose-optimizing study of 3 starting doses of ponatinib. *Blood*, 2022, 140, suppl., s. 1495–1497.

7 Hochhaus, A. – Rea, D. – Boquimpani, C., et al.: Asciminib vs bosutinib in chronic phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. *Leukemia*, 2023, 37, s. 617–626.

8 Hughes, T. P. – Mauro, M. J. – Cortes, J. E., et al.: Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. *N Engl J Med*, 2019, 381, s. 2315–2326.

9 Efficace, F. – Baccarani, M. – Breccia, M., et al.: Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. *Blood*, 2011, 118, s. 4554–4560.

10 Pemberton-Whiteley, Z. – Cortes, J. – Clements, J., et al.: Patient and physician perspectives of unmet needs in CML – designing the CML SUN Survey. *Blood*, 2021, 138, s. 4986–4988.

11 Bower, H. – Björkholm, M. – Dickman, P. W., et al.: Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. *J Clin Oncol*, 2016, 34, s. 2851–2857.

12 Baccarani, M. – Saglio, G. – Goldman, J., et al.: Evolving concepts in management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. *Blood*, 2006, 108, s. 1809–1820.

13 Baccarani, M. – Cortes, J. – Pane, F., et al.: Chronic myeloid leukemia: An update of concepts and management recommendations of European Leukemia Net. *J Clin Oncol*, 2009, 27, s. 6041–6051.

14 Baccarani, M. – Deininger, M. W. – Rosti, G., et al.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, 2013, 122, s. 872–884.

15 Hochhaus, A. – Baccarani, M. – Silver, R. T., et al.: European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*, 2020, 34, s. 966–984.

16 Čičátková, P. – Žáčková, D.: Vysazování inhibitorů tyrozinkináz u pacientů s chronickou myeloidní leukémií ve studiích a klinické praxi. *Transfuzie Hematol Dnes*, 2020, 26, s. 281–293.

17 Čičátková, P. – Horňák, T. – Žáčková, D.: Chronická myeloidní leukemie – aktuální léčebné možnosti. *Farmakoterapie*, 2022, 18, suppl. 2, s. 8–15.

18 Čičátková, P. – Žáčková, D.: Postavení inhibitorů tyrozinkináz v léčbě chronické myeloidní leukemie. *Onkol Revue*, 2023, 10, s. 1–6.

19 Žáčková, D.: Chronická myeloidní leukemie – od poznání patogeneze k cílené léčbě onemocnění. *Acta Med*, 2022, 12, s. 102–108.

20 Čičátková, P. – Žáčková, D. – Horňák, T., et al.: Cévní nežádoucí účinky u pacientů s chronickou myeloidní leukémií při terapii inhibitory tyrozinkináz v každodenní klinické praxi. *Transfuzie Hematol Dnes*,

2023, 29, s. 29–37.

21 García-Gutiérrez, V. – Hernández-Boluda, J. C.: Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. *Front Oncol*, 2019, 9, s. 603.

22 Maiti, A. – Franquiz, M. – Ravandi, F., et al.: Venetoclax and BCR ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia Chromosome-positive advanced myeloid leukemias. *Acta Hematol*, 2020, 143, s. 567–573.

23 Dulucq, S. – Rigal-Huguet, F. – Nickolini, F. E., et al.: Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study. *Br J Haematol*, 2023, 201, s. 1116–1124.

24 Iurlo, A. – Cattaneo, D. – Artuso, S., et al.: Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: a feasible option also in the real-life. A Campus CML Study. *Front Oncol*, 2022, 12, s. 839915.

25 Richter, A. – Lübking, A. – Söderlund, S., et al.: Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. *Leukemia*, 2021, 35, s. 2416–2418.

26 Žáčková, D. – Faber, E. – Stejskal, L., et al.: Half: a prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. *Blood*, 2021, 138, suppl. 1, s. 3606.

27 Clark, R. – Polydoros, F. – Apperley, J., et al.: De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. *Lancet Haematol*, 2019, 6, s. e375–e383.

Dlouhodobé výsledky podání venetoclaxu s anti-CD20 protilátkou v časově omezené délce léčby – studie CLL14 a MURANO

MUDr. Heidi Móciková, Ph.D. Hematologická klinika FN KV a 3. LF UK, Praha

1 Fischer, K. – Al-Sawaf, O. – Bahlo, J., et al.: Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med*, 2019, 380, s. 2225–2236.

2 Al-Sawaf, O. – Zhang, C. – Tandon, M., et al.: Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 2020, 21, s. 1188–1200.

3 Al-Sawaf, O. – Robrecht, S. – Zhang, C., et al.: Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year

results of the randomized CLL14 study. Abstract No. S145. Dostupné z: <https://library.ehaweb.org/eha/2023/eha2023-congress/387845/>, vyhledáno 2. 10. 2023. Association 2023 Hybrid Congress, Frankfurt, Německo, 8–11. 6. 2023

4 Al-Sawaf, O. – Zhang, C. – Lu, T., et al.: Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. *J Clin Oncol*, 2021, 39, s. 4049–4060.

5 Urso, A. – Cavazzini, F. – Ballardini, M. P., et al.: First-line treatment of older patients with CLL: A new approach in the chemo-free era.

Cancers, 2023, 15, s. 3859.

6 Seymour, J. F. – Kipps, T. J. – Eichhorst, B., et al.: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*, 2018, 378, s. 1107–1120.

7 Seymour, J. F. – Kipps, T. J. – Eichhorst, B. F., et al.: Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. *Blood*, 2022, 140, s. 839–850.

8 Kater, A. – Harrup, R. – Kipps, T. J., et al.: S201: Final 7-year follow-up and retreatment substudy analysis of MURANO: venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic

leukemia (R/R CLL). *Hemasphere*, 2023, 7, suppl., e492813f.

9 **Kater, A. – Lu, T. – Langerak, A., et al.**: First chronic lymphocytic leukemia (CLL) clonal growth rate is lower following venetoclax-rituximab (VenT): results from a minimal residual disease (MRD) model

from the randomized phase 3 Murano trial. *Blood*, 2021, 138, suppl. 1, s. 1551–1551.

10 **Yang, S. – Kay, N. E. – Shi, M., et al.**: Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory

approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? *Leukemia*, 2022, 36, s. 2743–2747.

Vyxeos Liposomal a jeho role v terapii akutní myeloidní leukemie – první zkušenosti s jeho použitím v ÚHKT Praha – kazuistika

MUDr. Jan Válka, Ph.D. | MUDr. Petr Soukup, MHA Ústav hematologie a krevní transfuze, Praha

1 **Lancet, J. E. – Uy, G. L. – Cortes, J. E., et al.**: CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. *J Clin Oncol*, 2018, 36, s. 2684–2692.

2 **Lancet, J. E. et al.**: CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. *Lancet Haematol*, 2021, 8, s. e481–e491.

3 **Rautenberg, Ch. – Stölzel, F. – Röhlig, Ch., et al.**: Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. *Blood Cancer J*, 2021, 11, s. 164.

4 **Guolo, F. – Fianchi, L. – Minetto, P., et al.**: CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. *Blood Cancer J*, 2020, 10, s. 96.

5 **Chiche, E. – Rahmé, R. – Bertoli, S., et al.**: Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients:

a multicentric French cohort. *Blood Adv*, 2021, 5, s. 176–184.

6 Vyxeos Liposomal. SÚKL. Dostupné z: https://prehledy.sukl.cz/prehled_leciv.html#/, vyhledáno 21. 7. 2023.

7 Swixx Biopharma Vyxeos. Dostupné z: <https://www.adc.sk/databazy/produkty/dodavatele/swixx-biopharma-s-r-o-12909.html?n=Vyxeos&nai=&cla=&frm=&hol=&code=&mf=&cat=&ord=a1>, vyhledáno 21. 7. 2023.

Léčba belantamabem v pátém relapsu mnohočetného myelomu – kazuistika

MUDr. Jan Straub I. interní klinika – klinika hematologie, VFN a 1. LF UK, Praha

1 SPC přípravku Blenrep, www.sukl.cz.

2 **Lonial, S. – Lee, H. C., et al.**: Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or

intolerant to anti-CD38 monoclonal antibodies (mAbs). *J Clin Oncol*, 2020, 38, suppl. 15, s. 8536–8536.

3 **Lonial, S. – Jacobus, S. – Fonseca, R., et al.**: Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. *J Clin Oncol*, 2020, 38, s. 1126–1137.

4 **Dimopoulos, M. A. – Moreau, P. – Terpos, E., et al.**: Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2021, 32, s. 309–322.